Comparative single‐cell RNA sequencing analysis of immune response to inactivated vaccine and natural SARS‐CoV‐2 infection
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Shuai He und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Laboratory Center, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Innovation Project of Foshan Municipality, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Uncovering the immune response to an inactivated SARS‐CoV‐2 vaccine (In‐Vac) and natural infection is crucial for comprehending COVID‐19 immunology. Here we conducted an integrated analysis of single‐cell RNA sequencing (scRNA‐seq) data from serial peripheral blood mononuclear cell (PBMC) samples derived from 12 individuals receiving In‐Vac compared with those from COVID‐19 patients. Our study reveals that In‐Vac induces subtle immunological changes in PBMC, including cell proportions and transcriptomes, compared with profound changes for natural infection. In‐Vac modestly upregulates IFN‐α but downregulates NF‐κB pathways, while natural infection triggers hyperactive IFN‐α and NF‐κB pathways. Both In‐Vac and natural infection alter T/B cell receptor repertoires, but COVID‐19 has more significant change in preferential VJ gene, indicating a vigorous immune response. Our study reveals distinct patterns of cellular communications, including a selective activation of IL‐15RA/IL‐15 receptor pathway after In‐Vac boost, suggesting its potential role in enhancing In‐Vac‐induced immunity. Collectively, our study illuminates multifaceted immune responses to In‐Vac and natural infection, providing insights for optimizing SARS‐CoV‐2 vaccine efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Laboratory Center, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Medical Laboratory Center, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China.
- School of Medicine and Institute for Immunology, Tsinghua University, Beijing, China.
Förderung
- Science and Technology Innovation Project of Foshan Municipality
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
He, S., Liu, S. Q., Teng, X. Y., He, J. Y., Liu, Y., Gao, J. H., Wu, Y., Hu, W., Dong, Z. J., Bei, J. X., & Xu, J. H. (2024). Comparative single‐cell RNA sequencing analysis of immune response to inactivated vaccine and natural SARS‐CoV‐2 infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.29577
Vancouver
He S, Liu SQ, Teng XY, He JY, Liu Y, Gao JH, et al. Comparative single‐cell RNA sequencing analysis of immune response to inactivated vaccine and natural SARS‐CoV‐2 infection. Journal of Medical Virology. 2024. doi:10.1002/jmv.29577
BibTeX
@article{He2024,
author = {He, Shuai and Liu, Shu-Qiang and Teng, Xiang-Yun and He, Jin-Yong and Liu, Yang and Gao, Jia-Hui and Wu, Yue and Hu, Wei and Dong, Zhong-Jun and Bei, Jin-Xin and Xu, Jian-Hua},
title = {Comparative single‐cell RNA sequencing analysis of immune response to inactivated vaccine and natural SARS‐CoV‐2 infection},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29577}
}
EUVIMED